SCHEDULE 13G/A: Cystic Fibrosis Foundation Maintains Significant 19.99% Stake in BiomX Inc.

The Cystic Fibrosis Foundation has filed an amended Schedule 13G, reaffirming its beneficial ownership of 19.99% of BiomX Inc.'s common stock as of September 30, 2024.

Summary

• The Cystic Fibrosis Foundation (CFF) reported beneficial ownership of 4,094,558 shares of BiomX Inc. Common Stock.
• This ownership represents 19.99% of the outstanding Common Stock of BiomX Inc.
• The total beneficial ownership comprises 1,787,758 shares of Common Stock directly held, 1,308,800 shares underlying Series X Non-Voting Convertible Preferred Stock convertible within 60 days, and 998,000 shares underlying a warrant exercisable within 60 days.
• The warrant agreement includes a provision that prohibits the CFF from exercising it for such number of shares that would result in their beneficial ownership exceeding 19.99% of outstanding Common Stock.
• The percentage of class is calculated based on 18,176,602 shares of Common Stock outstanding as of November 12, 2024, as reported in BiomX Inc.'s Quarterly Report on Form 10-Q filed on November 14, 2024, plus the convertible preferred stock and warrant shares.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. The maintenance of a significant stake by a reputable foundation is mildly positive, indicating continued support, but there are no new operational or financial developments to significantly shift sentiment.

Positives

• The continued significant beneficial ownership by the Cystic Fibrosis Foundation (19.99%) indicates a stable, long-term institutional investment in BiomX Inc.
• The inclusion of convertible preferred stock and warrants suggests a strategic and potentially supportive relationship between the foundation and the company.

Negatives

• The warrant's contractual limitation preventing the Cystic Fibrosis Foundation from exceeding 19.99% beneficial ownership could cap their potential for increased direct influence or investment in the company.

Risks

• The document itself does not detail specific business risks for BiomX Inc., but the 19.99% ownership cap on the warrant could be a limitation if the Cystic Fibrosis Foundation intended to increase its stake beyond this threshold in the future.

Future Outlook

The document is a beneficial ownership filing and does not contain forward-looking statements or guidance regarding BiomX Inc.'s future performance or strategic outlook.

Industry Context

This filing indicates a significant, stable institutional investment in BiomX Inc., a biotechnology company. Such substantial stakes by non-profit foundations like the Cystic Fibrosis Foundation are common in the biotech sector, often reflecting strategic partnerships, research funding, or long-term commitment to specific disease areas, which can provide a degree of stability and validation for the company within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• BiomX Inc. Management: Awareness of a large, stable shareholder can influence strategic decisions and long-term planning.

Next Steps

• The document does not mention any specific future actions, events, or milestones for BiomX Inc. or the Cystic Fibrosis Foundation beyond the ongoing beneficial ownership.

Key Dates

Keywords

BiomX Inc., Cystic Fibrosis Foundation, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Warrant, SEC Filing, Institutional Investor, Biotechnology